Hematology

Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
(AbbVie) M20-178 / TRANSFORM-2A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in
Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory
Myelofibrosis (TRANSFORM-2)
Dr Brian LeberOpen to recruitmentNCT04468984
(AbbVie) M20-621A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in
Combination with R-CHOP Compared to R-CHOP in Subjects with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Dr Gwynivere DaviesOpen to recruitmentNCT05578976
(AbbVie) M24-108A Multicenter, Phase 1b, Open-label Study to Evaluate Dose Optimization Measures and Safety of ABBV-383 in Subjects with Relapsed or Refractory Multiple MyelomaDr Hira MianOpen to recruitmentNCT05650632
(AstraZeneca) D7230C00001A Modular Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0305 as Monotherapy or in Combination With Anticancer Agent(s) in Participants with Relapsed or Refractory Multiple MyelomaDr Hira MianOpen to recruitmentNCT06106945
(BMS) CA089-1043 / KarMMa-9A Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participants with Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell TransplantationDr Amaris BalitskySuspended/On holdNCT06045806
(CCTG) HD.11A Randomized Phase II Trial of Pembrolizumab and Brentuximab Vedotin versus GDP Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin LymphomaDr Amaris BalitskyOpen to recruitmentNCT05180097
(CCTG) LY.17A Multi-stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell LymphomaDr Graeme FraserSuspended/On holdNCT02436707
(CCTG) MY.13A PHASE III NON-INFERIORITY RANDOMIZED CONTROLLED TRIAL OF FIXED DURATION VERSUS CONTINUOUS DARATUMUMAB AMONG TRANSPLANT INELIGIBLE OLDER ADULTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOMADr Hira MianOpen to recruitmentNCT06182774
(EMN) EMN28 / 68284528MMY3005 / CARTITUDE-6A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant EligibleDr Mohammed AljamaOpen to recruitmentNCT05257083
(Genentech) GO42552 / CAMMA 1AN OPEN-LABEL, MULTICENTER, PHASE Ib TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF CEVOSTAMAB AS MONOTHERAPY AND CEVOSTAMAB PLUS POMALIDOMIDE AND DEXAMETHASONE OR CEVOSTAMAB PLUS DARATUMUMAB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (CAMMA 1)Dr Hira MianOpen to recruitmentNCT04910568
(Janssen) 64407564MMY3009 / MonumenTAL-6A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P),Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator’s Choice of EitherElotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, andDexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to4 Prior Lines of Therapy Including an Anti-CD38 Antibody and LenalidomideDr Hira MianOpen to recruitmentNCT06208150
(Kura Oncology) KO-MEN-001A Phase 1/2 First in Human Study of the Menin-MLL (KMT2A) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia.Dr Brian LeberOpen to recruitmentNCT04067336
(Pfizer) C1071007 / MAGNETISMM-7A RANDOMIZED, 2-ARM, PHASE 3 STUDY OF ELRANATAMAB (PF-06863135) VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO ARE MINIMAL RESIDUAL DISEASE POSITIVE AFTER UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATIONDr Mohammed AljamaOpen to recruitmentNCT05317416
(PharmaEssentia) A22-203 / ECLIPSEA Phase IIIb, Randomized, Open-Label, Parallel Group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon alfa-2b-njft (P1101) in Adult Patients with Polycythemia Vera (PV)Dr Christopher HillisOpen to recruitmentNCT05481151
(Roche) BP43437 / UniforMMAN OPEN-LABEL, RANDOMIZED PHASE Ib/II, STUDY EVALUATING SAFETY, TOLERABILITY, AND CLINICAL ACTIVITY OF RO7425781-BASED TREATMENT COMBINATIONS IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMADr Hira MianOpen to recruitmentNCT06055075
(SHSC) 3242 / BRAWMA Multi-Center, Open-Label, Single-Arm Phase II Trial of Bendamustine, Rituximab and the Second Generation BTK Inhibitor Acalabrutinib in Previously Untreated Waldenstrom’s MacroglobulinemiaDr Mohammed AljamaOpen to recruitmentNCT04624906
(Syros) SY-1425-301 / SELECT-MDS-1A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome Dr Brian LeberOpen to recruitmentNCT04797780
Download PDF